Hemato (Aug 2021)

Transcriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia

  • Shaun D. Patterson,
  • Xu Huang,
  • Heather G. Jørgensen,
  • Alison M. Michie

DOI
https://doi.org/10.3390/hemato2030035
Journal volume & issue
Vol. 2, no. 3
pp. 556 – 571

Abstract

Read online

Acute myeloid leukaemia (AML) is a haematological cancer with poor outcomes due to a lack of efficacious targeted therapies. The Nuclear Factor of Activated T Cells (NFAT) family of transcription factors is well characterised as a regulator of the cell cycle and differentiation in the myeloid lineage. Recent evidence has demonstrated that NFAT family members may have roles in regulating AML leukemogenesis and resistance to targeted therapy in myeloid leukaemia. Furthermore, gene expression data from patient samples show that some NFATs are more highly expressed in poorly differentiated AML and after disease relapse, implying that the NFAT family may have roles in specific types of AML. This review outlines the evidence for the role of NFAT in healthy myeloid tissue and explores how NFAT might regulate AML pathogenesis, highlighting the potential to target specific NFAT proteins therapeutically in AML.

Keywords